RenovoRx, Inc.

NASDAQ:RNXT

Biotechnology

Healthcare
$1.12 -0.86%

-$0.01 today

Market cap
$54.04M
Beta
0.99
P/E (TTM)
-3.4
EPS (TTM)
-$0.32
52W Low $0.70High $1.45

Volume 0.84M

Average 0.29M

RNXT Total Debt

Short-term and long-term borrowings combined.

RenovoRx, Inc.NASDAQ: RNXT

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 34.3% from a year ago

Total debt stood at $186K at the end of Q1 FY2026, down 34.3% from a year earlier and down 12.3% from the prior quarter.

Context

  • Total debt amounted to 1.3% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -34.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$186K-12.3% QoQ
Last fiscal yearDec 2025
$212K-23.7% YoY
Year agoMar 2025
$283K-34.3% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.3%——
1 year-23.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
212K USD
Year-over-year change
-23.7%

Total Debt vs competitors

How RNXT compares with its peers on the latest reported figures

  • RNXT's Mar 2026 total debt of $186K is the 3rd highest of the 6 companies compared; the peer median is $59.08K.
  • Its year-over-year change of -34.3% is the highest of 4, against a peer median of -69.7%.
  • Total debt amounts to 1.3% of total assets for RNXT, versus a peer median of 0.8%.
RNXT Competitors Peer median
Total Debt for RNXT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CELUCelularity Inc.Dec 2025$40.9M -40.6%-14.6%38.1%
PYPDPolyPid Ltd.Mar 2026$2.34M -73.5%-41.2%12.2%
RNXTRenovoRx, Inc.Mar 2026$186K -34.3%—1.3%
LTRNLantern Pharma Inc.Mar 2026$59.08K -69.7%+1040.9%0.8%
MAIAMAIA Biotechnology, Inc.Mar 2026$0 ——0.0%
ANVSAnnovis Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding RNXT) $59.08K-69.7%-14.6%0.8%

Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents15.19M4.39M1.17M7.15M7.02M
Short-term Investments02.05M000
Net Receivables00043K139K
Inventory0000189K
Other Current Assets0825K101K303K541K
Total Current Assets16.28M7.27M1.47M7.83M7.89M
Property, Plant & Equipment (Net)6K00290K202K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets6K00290K202K
Total Assets16.29M7.27M1.47M8.12M8.1M
Account Payables525K534K561K586K799K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities33K475K75K817K748K
Total Current Liabilities938K1.1M1.18M1.91M1.96M
Long-term Debt0000107K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities003.29M1.52M604K
Total Non-current Liabilities003.29M1.73M711K
Total Liabilities938K1.1M4.47M3.64M2.67M
Common Stock1K1K1K2K4K
Retained Earnings(21.28M)(31.17M)(41.41M)(50.22M)(61.39M)
Accumulated OCI(16.29M)17K000
Other Stockholders Equity00000
Minority Interest00000
Total Equity15.35M6.16M(3M)4.48M5.42M
Total Debt000278K212K
Net Debt(15.19M)(4.39M)(1.17M)(6.88M)(6.81M)

RenovoRx, Inc.

NASDAQ:RNXT

Intrinsic Alpha fair value

Locked

Current Price

$1.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.